From Clinical Endpoints to In Vitro Bioequivalence: Regulatory Evolution of Topical Generic Drug Approvals in the US and EU

The regulatory approach to topical generic drug development has changed significantly over the past decade. Traditional clinical endpoint studies, once considered the standard pathway for demonstrating bioequivalence, are now often viewed as costly, variable, and limited in their ability to detect formulation-driven differences.

In response, both the FDA and EMA have placed greater emphasis on in vitro methodologies, including IVRT and IVPT, as more practical and scientifically meaningful tools for supporting topical bioequivalence. This new Diteba Inc. white paper reviews that regulatory shift and explains how in vitro approaches are shaping the future of topical generic drug approvals in the United States and Europe.

The paper discusses:

• Why regulatory agencies are moving beyond traditional clinical endpoint studies
• The growing role of IVRT and IVPT in topical generic drug development
• How FDA and EMA expectations are changing for locally acting topical products
• Why formulation differences, product microstructure, and drug release/permeation behaviour matter
• How in vitro bioequivalence tools can support more efficient development programs
• What sponsors should consider when planning topical generic submissions in the US and EU

For pharmaceutical companies developing topical generic products, this paper offers a clear overview of where the regulatory landscape is heading and why an early in vitro strategy matters.

Diteba Inc. supports clients with IVRT and IVPT method development, validation, study execution, data interpretation, and regulatory strategy for topical and transdermal drug products. Our team helps sponsors design programs that are scientifically robust, practical, and aligned with current agency expectations.

Download the white paper to learn more about the move from clinical endpoints to in vitro bioequivalence for topical generic products. Contact Diteba to discuss how our IVRT/IVPT expertise can support your next topical drug development program.